Company History

Viral Genetics began in the early 90's when it was formed to study a compound called thymus nuclear protein or TNP. TNP had initially been studied as a means of detecting HIV infection however it was found that it had potential as an actual therapy for HIV/ AIDS. Our first drug candidate based on TNP was called VGV-1. We studied VGV-1 in six human clinical trials, the last of which was a 137-patient, multi-center, placebo-controlled trial in South Africa designated “Phase III” by South African Medicines Control Council. That clinical trial confirmed antiviral activity of TNP in some but not all patients infected with HIV. Under the advice of our leading HIV/AIDS advisors, we went back to the lab to study two things: how TNP had worked and what the specific active molecule(s) was.

Around this time we met Dr. M. Karen Newell-Rogers, who was then at the University of Colorado, Colorado Springs and is now at Texas A&M University. Dr. Newell-Rogers had been studying a method of turning certain immune system responses on or off using a theoretical and computer-designed molecule that was, in part, predicted to have certain effects on things like HIV infection that were remarkably similar to our actual clinical trial results using TNP. After several preliminary studies we found that Dr. Newell-Roger’s years of research meshed with our own clinical development history.

We entered into a series of agreements with the University of Colorado and Dr. Newell-Rogers that, over time and after much successful hard work, culminated in the two Exclusive License Agreements that now form the basis of our intellectual property portfolio and our ongoing R&D efforts. Part of this included expanding our technology to include a new line of research relating to Metabolic Disruption (MDT) – an area that holds promise in cancer therapy, wound healing and – to our surprise – production of plant oils and biofuels.

We are now focused on initiating clinical trial testing of compounds for HIV/AIDS, Lyme Disease, Staphylococcus, Streptococcus and Sepsis infection, glioblastoma (a form of brain cancer), and more. We are also commencing development of the biofuels applications of the MDT patents through our separate subsidiary, VG Energy.

2010 – Viral Genetics Establishes Texas R&D Facility as Dr. Newell-Rogers Transitions to Texas A&M University-Affiliated Scott and White Hospital.

• $750,000 grant to Dr. Newell-Rogers from Texas Emerging Technologies Fund to study biofuel applications of MDT
• Company establishes R&D lab in life sciences cluster in Georgetown, Texas and hires FDA liaison and lab operations manager

2009 – Finalized Exclusive Licenses for both TPT and MDT with University of Colorado and University of Vermont.

• Replaced option rights with outright licenses.
• Focus of ongoing research.

2008 – Continued to study TPT and began studying MDT.

• Expanded relationship with University of Colorado and University of Vermont through Exclusive Option Agreements (replaced)

2007 – Licensed TPT technology from University of Colorado with V-Clip Pharmaceuticals (wholly-owned subsidiary)

• believed to explain mechanism of action of VGV-1 and identify active molecules
• promised to accelerate dose optimization for second-generation drug
• studies successful

2006 – Completed double-blind, placebo-controlled study of VGV-1 (South African)

• 137-patient study designated “Phase III” by South African Medicines Control Council
• No apparent toxicities or significant adverse events related to drug observed
• 22% showed significant decrease in HIV viral load 100 days after treatment.
• Stronger results in later-stage, sicker patients – consistent with prior studies.

1995-2003 - Conducted five prospective studies of VGV-1 (China)

• No apparent toxicities observed
• Decrease in HIV viral load observed
• Studies focused on late-stage patients who had never received antiretroviral combination therapy previously

1992 - Haig Keledjian and Dr. Harry Zhabilov pursue thymus nuclear protein (“TNP”) as means of early-detection of HIV and cancer.

• additional study revealed TNP’s apparent effect on HIV /AIDS patients when suspended in adjuvant: “VGV-1”